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Abstract
Alzheimer’s disease (AD) is characterized by amyloid-beta (Aβ) deposits, which come in myriad morphologies with varying 
clinical relevance. Previously, we observed an atypical Aβ deposit, referred to as the coarse-grained plaque. In this study, 
we evaluate the plaque’s association with clinical disease and perform in-depth immunohistochemical and morphological 
characterization. The coarse-grained plaque, a relatively large (Ø ≈ 80 µm) deposit, characterized as having multiple cores 
and Aβ-devoid pores, was prominent in the neocortex. The plaque was semi-quantitatively scored in the middle frontal gyrus 
of Aβ-positive cases (n = 74), including non-demented cases (n = 15), early-onset (EO)AD (n = 38), and late-onset (LO)AD 
cases (n = 21). The coarse-grained plaque was only observed in cases with clinical dementia and more frequently present in 
EOAD compared to LOAD. This plaque was associated with a homozygous APOE ε4 status and cerebral amyloid angiopa-
thy (CAA). In-depth characterization was done by studying the coarse-grained plaque’s neuritic component (pTau, APP, 
 PrPC), Aβ isoform composition (Aβ40, Aβ42, AβN3pE, pSer8Aβ), its neuroinflammatory component (C4b, CD68, MHC-II, 
GFAP), and its vascular attribution (laminin, collagen IV, norrin). The plaque was compared to the classic cored plaque, 
cotton wool plaque, and CAA. Similar to CAA but different from classic cored plaques, the coarse-grained plaque was pre-
dominantly composed of Aβ40. Furthermore, the coarse-grained plaque was distinctly associated with both intense neuroin-
flammation and vascular (capillary) pathology. Confocal laser scanning microscopy (CLSM) and 3D analysis revealed for 
most coarse-grained plaques a particular Aβ40 shell structure and a direct relation with vessels. Based on its morphological 
and biochemical characteristics, we conclude that the coarse-grained plaque is a divergent Aβ plaque-type associated with 
EOAD. Differences in Aβ processing and aggregation, neuroinflammatory response, and vascular clearance may presumably 
underlie the difference between coarse-grained plaques and other Aβ deposits. Disentangling specific Aβ deposits between 
AD subgroups may be important in the search for disease-mechanistic-based therapies.
Keywords Amyloid-beta · Coarse-grained plaque · Early-onset Alzheimer’s disease · Cerebral amyloid angiopathy · 
Neuroinflammation
Introduction
Amyloid-beta (Aβ) plaques and hyperphosphorylated tau 
(pTau) tangles are the main pathological hallmarks of Alz-
heimer’s disease (AD). Aβ plaques originate from the accu-
mulation and aggregation of the Aβ peptide, which is formed 
by the sequential cleavage of the amyloid precursor protein 
by β- and γ-secretases [21]. Depending on the cleavage site 
of γ-secretase, the Aβ peptide length may vary from 36 to 
43 amino acids, with Aβ40 and Aβ42 being the most com-
mon forms found in AD. The longer Aβ42 is more prone 
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to aggregate and is predominantly found in parenchymal 
plaques, whereas the shorter Aβ40 is secreted by cells in 
higher levels and is the major Aβ isoform deposited in the 
cerebral vasculature, referred to as cerebral amyloid angio- 
pathy (CAA) [5, 6, 28]. The Aβ peptide can undergo several 
post-translational modifications resulting, e.g., in truncated 
pyroglutamate Aβ (AβN3pE) and Aβ phosphorylated at serine 
8 (pSer8Aβ) [30–32]. These different Aβ isoforms are asso-
ciated with clinical disease progression and are considered 
to mark sequential phases of plaque and CAA maturation 
[20, 43, 52].
Since the first description of AD, many different types of 
amyloid deposits have been described, which vary in their 
association with clinical symptoms [18, 19, 39, 48, 49]. 
The currently used categorization scheme for both cerebral 
parenchymal and vascular Aβ deposits, referred to as plaques 
and CAA, respectively, are both described by Thal et al. [48, 
49]. The first categorization step for plaques is based on 
their fibril content, since the fibrillar type is better associated 
with clinical dementia than the non-fibrillar type [11, 44]. 
Fibrillar plaques can range in size from 30 to 100 μm cross-
sectionally and contain Aβ in a β-pleated sheet secondary 
conformation, also referred to as amyloid. Amyloid plaques 
are further ordered into compact or cored-only plaques, and 
classic cored plaques [16, 48]. Non-fibrillar or better known 
as diffuse plaques, can range from 10 to > 100 μm cross-
sectionally with a great variation in morphology [48]. Con-
trary to fibrillar plaques, diffuse plaques are often present 
in cases without cognitive impairment [3, 12, 40]. The next 
categorization step is the presence of a neuritic component. 
A plaque is considered neuritic when the focal Aβ deposit 
contains degenerating axons and dendrites referred to as 
dystrophic neurites. The load of these neuritic plaques in 
the neocortex correlates well with clinical disease severity 
[34]. Besides the common plaque variants, more rare plaque 
types such as the cotton wool plaque are described. These 
plaques are clinically relevant as, although reported in a few 
sporadic cases, they are predominantly described in patients 
with specific PSEN1 mutations [10, 47]. For vascular Aβ 
deposits, CAA is categorized as either CAA-Type 1 involv-
ing cortical capillaries in additional to leptomeningeal and 
cortical arteries and arterioles, and CAA-Type 2 not involv-
ing cortical capillaries [49].
We recently observed a plaque morphology that did not fit 
the afore mentioned descriptions [7]. Comparing AD related 
pathology in a small cohort of different AD subtypes, we 
observed a relatively large plaque with a coarse-grained 
structure using anti-Aβ immunostaining. According to our 
knowledge, these coarse-grained plaques have not yet been 
well-described. In the current study, we describe the coarse-
grained plaque and investigate its presence in a cohort 
(n = 74) of EOAD, LOAD, and Aβ-positive non-demented 
cases. We further characterize the coarse-grained plaque by 
comparing it to other clinically relevant Aβ deposits, being 
the classic cored plaque, the cotton wool plaque, and CAA-
Type 1. Confocal laser scanning microscopy (CLSM) was 
used to image the coarse-grained plaque in 3D.
Methods
Post‑mortem brain tissue
Post-mortem brain tissue was obtained from the Netherlands 
Brain Bank (NBB; Amsterdam, The Netherlands, https ://
www.brain bank.nl) and the Normal Aging Brain Collection 
(NABCA; Amsterdam UMC - location VUmc, Amsterdam, 
The Netherlands, http://nabca .eu). In compliance with all 
ethical standards, brain donors signed informed consent 
regarding the usage of their brain tissue and clinical records 
for research purposes. The local medical ethics committee 
of the VUmc approved the brain donor programs of the NBB 
and NABCA. Brain dissection and neuropathological diag-
nosis were performed according to international guidelines 
of Brain Net Europe II (BNE) consortium (http://www.brain 
net-europ e.org) and NIA-AA [35]. Aβ-positive cases were 
selected if cognitive decline was not reported during life, Aβ 
deposits were present in the brain, i.e., Aβ-positive, and total 
AD neuropathologic score according to the NIA-AA was 
‘low’ [35]. Aβ-positive cases were age- and sex-matched 
to late-onset AD (LOAD) cases. AD cases were selected 
based on dementia diagnosis during life in combination with 
an intermediate or high score for AD pathology [35]. This 
resulted in a cohort of 15 Aβ-positive cases, 38 early-onset 
AD (EOAD) -, and 21 LOAD cases. Additional cases, con-
taining cotton wool plaques (n = 4) and CAA-Type 1 (n = 3) 
were included for the comparison to different types of Aβ 
deposits. For all cases, Thal phase for Aβ, Braak stage for 
neurofibrillary tangles [8], Thal stage for CAA [50] and 
concomitant pathologies, i.e., Lewy bodies [1], TDP43 
pathology [36], and vascular lesions were reported when 
the respective assessment was readily available from the 
brain bank (see Supplementary Material 1, Table S1, Online 
Resource, for case details).
Formalin (4%)-fixed paraffin-embedded (FFPE) tissue 
blocks of the right middle frontal gyrus were used. In addi-
tion, for 14 cases (Supplementary Material 1, Table S1, 
Online Resource) also FFPE blocks of the right temporal 
-, parietal -, occipital-, olfactory cortex, pre- and postcen-
tral gyrus, amygdala, hippocampus (including CA1-CA4, 
dentate gyrus, subiculum, and entorhinal cortex), caudate 
nucleus, putamen, substantia nigra, locus coeruleus, pons, 
medulla oblongata, and cerebellum were used. For 1 of 4 
cotton wool cases, the superior parietal lobule region was 
included due to tissue region availability within the NBB. 
For CAA-Type 1 comparison, the occipital cortex was used, 
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as this region is most prone to CAA pathology [6]. FFPE 
tissue was cut at 6 μm thickness for immunohistochemis-
try and at 5 μm thickness for multi-label immunofluores-
cence. Formalin-fixed free-floating (FFFF) (4% formalin; 
for 24–36 h) tissue from the left middle frontal gyrus of 
5 AD cases (Supplementary Material 1, Table S1, Online 
Resource) was used for 3D multi-label immunofluorescence 
confocal imaging. FFFF tissue was put on sucrose (15%; 
30%) for cryopreservation, stored at − 80 °C and cut on a 
sliding microtome in 60 μm-thick sections.
Genotyping
DNA was extracted from blood or brain tissue and apoli-
poprotein genotype (APOE) was determined for 72 of 74 
cases and 3 of 4 cotton wool cases using methods previ-
ously described (Supplementary Material 1, Table  S1, 
Online Resource) [54]. Whole-exome sequencing (WES) 
was performed for 64 of 74 cases and for 3 of 4 cotton 
wool cases. For WES, exome-DNA was captured using the 
SeqCap EZ Human Exome Library v3.0 capture Kit or the 
Agilent SureSelect V6 kit (58 M); 150 bp paired-end reads 
were generated on the Illumina platform, with a mean depth 
of coverage of at least 30 × across exons. We performed in 
house alignment and quality control. The exomes of the 
genes APP (NM_000484.3), PSEN1 (NM_000021.3), and 
PSEN2 (NM_000447.2) were analyzed for likely pathogenic 
(class 4) or pathogenic (class 5) variants according to variant 
classification consensus guidelines [42]. Known pathogenic 
mutations are reported (Supplementary Material 1, Table S1, 
Online Resource).
(Immuno)histochemistry
(Immuno)histochemistry was performed on sequential sec-
tions for hematoxylin and eosin (H&E), Congo red, Aβ (aa 
8-17), Aβ40, Aβ42, AβN3pE, pSer8Aβ, APP,  PrPC, pTau, C4b, 
MHC-II, GFAP, norrin, laminin, collagen IV, and ApoE (see 
Supplementary Material 1, Table S2 for antibody—and 
staining specifics, Online Resource). After deparaffiniza-
tion, (immuno)histochemistry was performed according to 
the following protocols. H&E was performed by submerging 
sections in hematoxylin (5 min), followed by submerging in 
eosin (3 min). Histochemistry for Congo red was performed 
by incubation with a saturated sodium chloride solution (3% 
NaCl in 80% ethanol and 1% 1 M NaOH) followed by incu-
bation with a saturated Congo red solution (0.25% Congo 
red in 80% ethanol and 1% 1 M NaOH), both for 20 min at 
room temperature. Endogenous peroxidase was quenched 
using 0.3%  H2O2 in either phosphate buffered saline (PBS; 
pH 7.4) or methanol. This was followed by the appropriate 
antigen retrieval and primary antibody incubation. Subse-
quently, sections were incubated with a secondary antibody, 
followed by color development using 3,3’-diaminobenzidine 
(DAB) (Agilent-Dako) and counterstained using haematoxy-
lin. In between steps, sections were rinsed in PBS. Finally, 
sections were mounted with Quick-D (Klinipath) or Entellan 
(Sigma-Aldrich) and coverslipped. The omission of primary 
antibodies was used as negative control.
Multi‑label immunofluorescence
Multi-labeling on 5 µm sections was performed on case #18, 
32, 35, 39, 56, 64, 68, and all cotton wool cases (#75, 76, 
77, 78) for neuroinflammatory markers and vascular-asso-
ciated markers. Double-labeling for Aβ40 and Aβ42 was in 
addition to the above-mentioned cases, also performed on 
case #79, 80, 81. See Supplementary Material 1, Table S2, 
Online Resource, for antibody and staining details. After 
deparaffinization, sections stained for markers reflecting 
neuroinflammation were heated in citrate buffer (pH 6.0) 
using an autoclave and subsequently incubated overnight 
with a cocktail of antibodies directed against C4b, CD68, 
and GFAP. The following day, sections were incubated for 
1 h with a cocktail of the appropriate secondary antibodies 
(dilution 1:250). Antibody retrieval for sections stained for 
vascular-associated markers entailed submerging sections 
in Tris–EDTA buffer (pH 9.0) and heating them using an 
autoclave. Primary antibody incubation was done sequen-
tially, since both primary antibodies for vascular-associated 
markers were raised in rabbit. First, sections were incubated 
with anti-laminin overnight, followed by incubation with 
EnVision (Dako), rinsed in Tris-buffered saline (TBS pH 
7.6) and color development by tyramide reagent Alexa 568 
(1:100 in 0.0015%  H2O2 in TBS). Sections were heated in 
Tris–EDTA buffer using a microwave to ensure primary 
antibody detachment. Subsequently, sections were incu-
bated with anti-norrin and anti-Aβ aa 1-16 directly labeled 
Alexa 488. Norrin was visualized by incubating sections 
for 1 h with secondary antibody goat-anti-rabbit Alexa 647 
(dilution 1:250). Multi-label staining for Aβ isoform stain-
ing was performed by submerging sections in 98% formic 
acid for 5 min, followed by incubation with a cocktail of 
primary antibodies overnight and secondary antibodies the 
next day for 1 h. All sections were enclosed with 80% glyc-
erol/20% TBS. In between steps, sections were rinsed in 
PBS. All antibodies were diluted in normal antibody dilution 
(ImmunoLogic).
Multi-labeling on 60 µm FFFF sections was performed 
on case #29, 30, 42, 53, and 74. Sections were stained for 
neuroinflammatory markers (CD68 and GFAP together with 
Aβ aa 1-16), vascular markers (norrin and laminin together 
with Aβ aa 1-16), or Aβ40 together with Aβ42 (see Supple-
mentary Material 1, Table S2, Online Resource). Antigen 
retrieval was performed for neuroinflammatory and vas-
cular markers by heating sections in a water bath to 95 °C 
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for 30 min in either citrate buffer (pH 6.0) or Tris–EDTA 
buffer (pH 9.0). Sections double-labeled for Aβ40 and Aβ42 
were submerged in formic acid 99% for 10 min. All sec-
tions were rinsed in 2% bovine serum albumin (BSA) in 
TBS to block non-specific binding sites in the tissue sample 
and prevent non-specific antibody binding. Since some pri-
mary antibodies were raised in the same species, staining 
for neuroinflammatory and vascular markers was performed 
for each antigen sequentially using consecutive incubation 
steps. After the first primary antibody incubation with either 
anti-CD68 or anti-laminin, sections were incubated with a 
biotinylated secondary antibody directed against the appro-
priate species. This was followed by the ABC method and 
color development using tyramide reagent (Alexa 594 for 
CD68; Alexa 555 for laminin). Sections were re-heated in 
the water bath to 95 °C for 30 min to ensure the detach-
ment of the primary antibody. The potential residual pri-
mary antibody sites were then blocked by incubation for 1 h 
with normal serum (2%) of the appropriate species. This 
was followed by incubation with the next primary antibody 
(anti-GFAP or anti-norrin) and secondary antibody (goat-
anti-chicken Alexa 555 or goat-anti-rabbit Alexa 647). The 
staining procedure was finalized by incubation with anti-Aβ 
aa 1-16 directly labeled Alexa 488. Staining for Aβ40 and 
Aβ42 was performed using a cocktail of antibodies and visu-
alized with goat-anti-mouse-IgG2 Alexa 488 and goat-anti-
mouse-IgG1 Alexa 647. All sections were mounted with 
0.3% gelatin in Tris–HCl (0.05 M; pH 7.6), enclosed with 
Mowiol and DABCO and coverslipped. In between steps, 
sections were rinsed in TBS. For all multi-labeling experi-
ments, the omission of primary antibodies was used as a 
negative control and the color development step with tyra-
mide was performed after the detachment step to check if 
primary antibody detachment was successful.
Confocal imaging
CLSM was performed with a Nikon A1R HD microscope 
(Nikon, Amsterdam, the Netherlands) using a CFI Plan 
Apochromat λ 100x oil, NA 1.45, WD 0.13 objective lens. 
Scanning was done using galvano with scan size 1024 × 1024 
pixels, pixel size: 0.12 μm, and a pixel dwell time of 1.1 μs. 
Signal detection was performed using an A1-DUS spectral 
detector unit. Pinhole size was adjusted per experiment. 
The pinhole size was set to 57.5 μm for all IF stained FFPE 
sections (5 μm). For FFFF sections (60 μm), the pinhole 
radius was set to 20.4 μm for Aβ40 and Aβ42 combination, 
to 66.4 μm for neuroinflammatory marker combination (Aβ, 
CD68, and GFAP), and to 63.9 μm for vascular marker com-
bination (Aβ, laminin, and norrin). Sections were irradiated 
with a laser combination of wavelength 488, 514, 594, and 
640 nm, depending on fluorochrome combination. FFPE sec-
tions (5 μm) were imaged in 2D. For a 3D reconstruction of 
coarse-grained plaques, Z-steps of 0.25 μm were taken during 
the scanning of FFFF sections. For FFPE sections, no line 
integration was performed. For FFFF sections, line integration 
was set to 8 × for neuroinflammatory marker stained sections, 
to 4 × for vascular marker stained sections, and to 4 × for Aβ40 
and Aβ42 stained sections. The spectrum profile of each fluo-
rochrome was acquired from single stains. The autofluorescent 
spectrum was acquired from negative control sections. Images 
were spectrally unmixed using the appropriate spectra in the 
NIS-Elements AR software (Nikon).
3D Image processing and qualitative analysis 
of coarse‑grained plaques
Coarse-grained plaques were selected and subsequently 
scanned based on their 2D morphology in Aβ aa 1-16, Aβ40, 
or norrin staining with the CSLM. In total, 118 plaques were 
qualitatively analyzed in 5 cases (Supplementary Material 1, 
Table S3, Online Resource). The GFAP—Alexa 555 signal 
that was used for the neuroinflammation protocol in FFFF sec-
tions, decreased along the z axis due to spherical aberration. 
This effect was post-imaging corrected in Imaris software (ver-
sion 9.3.1, Oxford Instruments) by normalizing all layers. Post-
imaging processing was performed for all FFFF z-stacks using 
the denoise.AI algorithm in NIS-Elements imaging software 
(version 5.20.01, Nikon). Movies were annotated using Adobe 
After Effects (version 16.1, Adobe Systems Incorporated). All 
figures were composed using Adobe Photoshop (CS6, Adobe 
Systems Incorporated).
Semi‑quantitative scoring of the coarse‑grained 
plaque
In anti-Aβ immunohistochemistry, the coarse-grained plaque 
is defined by its size (30-100 µm), coarse-grainy deposits with 
multiple intensely stained cores, Aβ-devoid pores, and an ill-
defined border (see “Results” section). Its presence was semi-
quantitatively scored independently by two assessors (BDCB, 
MB) after anti-Aβ (aa 8-17; 6F/3D) staining. The assessors 
were blinded for group (Aβ-positive cases, EOAD, or LOAD) 
during the scoring process. Interrater reliability for the semi-
quantitative scoring of the coarse-grained plaque was substan-
tial (Cohen’s κ = 0.78) [9]. The scoring system was comprised 
of the following 4 categories: 0, no coarse-grained plaques 
per 1 cm2; 1, sparse (> 0 and < 6 coarse-grained plaques per 
1 cm2); 2, moderate (≥ 6 and ≤ 30 coarse-grained plaques 
per 1 cm2); and 3, frequent (> 30 coarse-grained plaques 
per 1 cm2). See Supplementary Material 1, Fig. S4, Online 
Resource, for representative figures per category.
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Laser‑capture microdissection of coarse‑grained 
plaques for ELISA analysis
Snap-frozen brain tissue of 2 cases with a frequent score 
for coarse-grained plaques (#18 and 32) was sectioned at 
25 µm and mounted on Leica Frame Slides (Leica Microsys-
tems, Danvers, MA, USA). Mounted brain sections were 
stained with thioflavin S to identify fibrillar amyloid plaques. 
Per case, a total of 1200 individual coarse-grained amy-
loid plaques were identified, excised, and captured using 
a laser-capture microdissection microscope LMD6 (Leica 
Microsystems) (See Supplementary Material 1, Fig. S5, 
Online Resource, for visualization of plaque laser micro-
dissection). The microdissected plaques were collected into 
100 µl of 10 mM sodium phosphate buffer, pH 7.2, contain-
ing 0.01% sodium azide.
Aβ ELISA analysis of captured coarse‑grained 
plaques
For the analysis of Aβ composition, 10 µl of the collected 
plaque suspension was added to 90 µl 5 M Guanidine HCl, 
50 mM Tris–HCl, pH 8.0. The samples were then diluted 
1:200 and subjected to sandwich ELISA analysis for the 
measurement of Aβ40 and Aβ42 peptides as described [13, 
29]. Briefly, in the sandwich ELISAs Aβ40 and Aβ42 were 
captured using their respective carboxyl-terminal specific 
antibodies mAb2G3 and mAb21F12 and biotinylated m3D6, 
specific for N-terminus of human Aβ, was used for detec-
tion [29]. Each plaque collection sample was measured in 
triplicate and compared to linear standard curves generated 
with known concentrations of human Aβ40 and Aβ42 using 
a Spectramax M2 plate reader (Molecular Devices, Sunny-
vale, CA).
Statistical analysis
Demographics of Aβ-positive cases, EOAD, and LOAD 
were compared using Chi square test for categorical data and 
ANOVA for numerical data. Since Aβ-positive cases were 
age- and sex- matched to LOAD, age and sex comparison 
was only performed for EOAD versus LOAD. Chi square 
test was performed to study the presence of coarse-grained 
plaques in relation to group (Aβ-positive cases, EOAD, and 
LOAD), APOE ε4 status (non-carrier, ε4 heterozygous, and 
ε4 homozygous), and CAA-Type (no CAA, CAA-Type 1, 
and CAA-Type 2). Post hoc Chi square test was performed 
when initial test was significant. A p value of < 0.05 was 
considered significant. Statistical analysis was performed in 
IBM SPSS version 22.0.
Results
Description and localization of the coarse‑grained 
plaque
Morphologically the coarse-grained plaque showed a multi-
cored, coarse-grainy appearance with pores devoid of Aβ 
(Fig. 1a). The coarse-grained plaque is usually relatively 
Fig. 1  The coarse-grained plaque and its localization. a The coarse-
grained plaque was defined using Aβ immunohistochemistry (aa 
8-17; 6F/3D) by its size (30–100  µm), coarse-grainy deposits with 
the appearance of multiple cores, Aβ-devoid pores, and a vague rim. 
Tubular-like structures (arrowhead) were seen within the plaque. b 
The coarse-grained plaque was predominantly found in layers II–IV 
of sulcal fundi and c near CAA-affected vessels. Scale bar is applica-
ble to all images and represents 10 µm in a, 400 µm in b, and 200 µm 
in c. Aβ amyloid-beta, CAA cerebral amyloid angiopathy
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large, with a diameter (Ø) ranging between 50 and 100 µm. 
However, smaller variants (Ø ≈ 30 µm) were also observed. 
Tubular-like or trabecular structures were seen within the 
plaque. Immunostaining directed against Aβ (aa 8-17; 
6F/3D) revealed a somewhat ill-defined plaque border 
(Figs. 1a, 3a). The plaques were predominantly found in 
layers II–IV, but when frequently present also in layers V 
and VI. The coarse-grained plaques were mostly observed 
in clusters in the fundi of cortical sulci (Fig. 1b) and near 
CAA-affected vessels (Fig. 1c). In summary, using anti-Aβ 
immunohistochemistry the coarse-grained plaque can be dis-
tinguished by its size (30-100 µm), coarse-grainy deposits 
with the appearance of multiple cores, Aβ-devoid pores, and 
a vague rim. In a subset of cases (n = 14) the plaque’s pres-
ence was scored in 20 brain regions additional to the middle 
frontal gyrus (Supplementary Material 1, Fig. S6, Online 
Resource). The coarse-grained plaque was predominantly 
found in the frontal and parietal regions and to a lesser 
extend also in the temporal and occipital regions of the neo-
cortex. The coarse-grained plaque was moderately observed 
in the limbic regions, being mostly the olfactory cortex and 
amygdala and occasionally the hippocampus. The coarse-
grained plaque was not observed in the basal ganglia. In 
one case, a few coarse-grained plaques were observed in the 
olivary nuclei and in another case one coarse-grained plaque 
was seen in the cerebellum. Other cases did not show coarse-
grained plaques in the brain stem areas or cerebellum.
Clinical relevance of the coarse‑grained 
plaque
Cohort description
We investigated the clinical relevance of the coarse-grained 
plaque by scoring the plaque in a cohort including EOAD 
and LOAD cases as well as non-demented Aβ-positive cases 
(see Supplementary Material 1, Table S1, Online Resource, 
for individual case details; Table 1 for group demographics; 
Fig. 2a for coarse-grained plaque scoring results per group). 
The EOAD group differed from the Aβ-positive group in 
their age at death and, as per definition, disease duration 
and AD pathology. EOAD cases had higher Braak stages for 
neurofibrillary tangles compared to LOAD cases (p < 0.01). 
Parenchymal CAA was seen in 66% of Aβ-positive cases, in 
100% of EOAD, and in 91% of LOAD. Of the Aβ-positive 
cases that were tested for APOE, only 31% had an ε4 allele 
and all ε4 carriers were heterozygous. In the EOAD group 
58% of cases was ε4 positive compared to 86% of LOAD 
cases. The EOAD ε4 positive group consisted of relatively 
more ε4 homozygous cases (36%) than the LOAD ε4 
group (17%). In 5 cases of the EOAD group an autosomal 
dominant mutation was found in either the PSEN1 (n = 4) 
or APP gene (n = 1) (Supplementary Material 1, Table S1, 
Online Resource).
The coarse‑grained plaque is associated 
with an early disease onset and a homozygous APOE 
ε4 status
Coarse-grained plaques were not observed in the non-
demented Aβ-positive cases (with the exception of 1 coarse-
grained plaque in the middle frontal gyrus of case #7). In 
contrast, the plaque was present in 66% of LOAD and in 
95% of EOAD patients (Fig. 2a). Extensive genotyping 
for (likely) pathogenic mutations in the APP, PSEN1, and 
PSEN2 genes was performed for 64 cases. In 5 genotyped 
cases with such a mutation, coarse-grained plaques were 
observed in either a sparse (n = 2), moderate (n = 1) or fre-
quent (n = 2) amount (Supplementary Material 1, Table S1, 
Online Resource). Although coarse-grained plaques were 
observed in both ε4 carriers and ε4 non-carrier AD cases, 
the plaque was especially prevalent in individuals homozy-
gous for the ε4 allele (p < 0.01) (Fig.  2b). Moreover, 
Table 1  Group demographics
Data are mean ± SD; age at onset, disease duration, and age at death 
shown in years; Aβ-positive cases were age- and sex-matched to 
LOAD. Statistical analysis was performed for group differences 
between Aβ-positive cases versus EOAD and EOAD versus LOAD 
using ANOVA for continuous data and (post hoc) Chi square test for 
categorical data
Aβ amyloid-beta, EOAD early-onset Alzheimer’s disease, LOAD late-
onset Alzheimer’s disease, n number, NA non-applicable, SD standard 
deviation
*p < 0.05; **p < 0.01; ***p < 0.001
Aβ-positive cases EOAD LOAD
n = 15 n = 38 n = 21
Male, n (%) 8 (53) 25 (66) 9 (43)
Age of onset NA 55 (± 8)*** 76 (± 6)***
Disease duration NA 10 (± 6)*** 8 (± 3)
Age at death 80 (± 9) 65 (± 9)*** 85 (± 6)***
ABC [35]
 A: n per stage 
0/1/2/3
0/13/2/0 0/0/0/38*** 0/0/0/21
 B: n per stage 
0/1/2/3
1/11/3/0 0/0/0/38*** 0/0/4/17**












Fig. 2  Clinical relevance of coarse-grained plaques. a Coarse-grained 
plaques were generally not observed in Aβ-positive non-demented 
cases, except for 1 coarse-grained plaque in 1 case. Coarse-grained 
plaques were more frequently seen in EOAD compared to LOAD. b 
The plaque’s presence was related to a homozygous APOE ε4 status. 
APOE status was known for 72 of 74 cases. c The coarse-grained 
plaque was not observed in cases devoid of CAA. d Figure legend is 
applicable to all 3 previous graphs. Aβ amyloid-beta, CAA cerebral 
amyloid angiopathy, EOAD early-onset Alzheimer’s disease, LOAD 
late-onset Alzheimer’s disease. Statistical analyses was performed 
using (post hoc) Chi square test; *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 3  Histology of the coarse-grained plaque compared to the cot-
ton wool and classic cored plaque. a Anti-Aβ (6F/3D) staining showed 
that the coarse-grained plaque is relatively large (⌀ ≈ 80  µm), contains 
Aβ-devoid pores, and has an ill-defined border. b The coarse-grained 
plaque showed tissue distortion in H&E. c Congo red staining for the 
coarse-grained plaque demonstrated fibrillar amyloid not condensed in 
one core. d When the coarse-grained plaque contained pTau immuno-
reactive dystrophic neurites, the plaque-center was often devoid of pTau 
immunoreactivity. e, f The cotton wool plaque showed a distinct circum-
scribed border in both anti-Aβ (6F/3D) as well as H&E staining. g The 
cotton wool plaque lacked clear amyloid. h Neuritic threads indicated by 
pTau immunoreactivity, but not dystrophic neurites were seen within the 
cotton wool plaque. i The classic cored plaque demonstrated a central 
amyloid core, which was surrounded by a corona of non-fibrillar Aβ. j–l 
Central pit in classic cored plaques was visible in H&E as well as Congo 
red staining and was often surrounded by dystrophic neurites (pTau). 
Scale bar represents 50 µm and is applicable to all images. Aβ Amyloid-
beta, H&E hematoxylin–eosin, pTau hyperphosphorylated tau
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homozygous carriers of the ε4 allele (n = 11; 3 LOAD, 8 
EOAD), always showed a moderate to frequent amount of 
coarse-grained plaques.
The coarse‑grained plaque is associated with CAA‑Type 1
Due to our previous observation that coarse-grained plaques 
often neighboured CAA-affected vessels, we investigated the 
co-occurrence of coarse-grained plaques with the presence 
and type of CAA [49] (Fig. 2c). Note that only 7 cases were 
devoid of CAA, of which 2 were cases with clinical AD. The 
coarse-grained plaque was only observed in cases with CAA. 
A frequent degree of coarse-grained plaques was observed 
in 47% of cases with CAA-Type 1 and in 14% of cases with 
CAA-Type 2. The presence of CAA-Type 1 was correlated 
to the presence of coarse-grained plaques (p < 0.001).
In‑depth characterization 
of the coarse‑grained plaque
Coarse‑grained plaques are different from cotton 
wool and classic cored plaques
In-depth (immuno)histochemical characterization was per-
formed by comparing the coarse-grained plaque to other 
clinically relevant plaques, i.e., the cotton wool plaque and 
the classic cored plaque (Figs. 3, 4, 5, 6, 7 and 8). See Table 2 
for a complete summary of each (immuno)histochemical 
staining per investigated plaque-type. After H&E staining, 
the coarse-grained plaque showed tissue distortion without a 
sharply defined outline (Fig. 3b). The plaque contained amy-
loid fibrils as visualized by Congo red staining (Fig. 3c). Neu-
ropil threads positive for pTau were always observed in and 
around the coarse-grained plaque (Fig. 3d). Dystrophic neur-
ites positive for pTau were often, but not always visible within 
coarse-grained plaques. When present, the neurites were rela-
tively less swollen compared to neurites seen in classic cored 
Fig. 4  ApoE, APP, and  PrPC 
immunoreactivity of the coarse-
grained plaque compared to the 
cotton wool and classic cored 
plaque. a ApoE was abundantly 
present all through the coarse-
grained plaque. b Dystrophic 
neurites immunoreactive for 
APP were found throughout 
the coarse-grained plaque. c 
The coarse-grained plaque was 
immunoreactive for  PrPC. d The 
cotton wool plaque stained posi-
tive for ApoE. e APP dystrophic 
neurites were negligibly visible 
in the cotton wool plaques. f 
 PrPC was observed in cotton 
wool plaques. g ApoE was 
found in both the corona and 
core of the classic cored plaque. 
ApoE staining intensity was 
highest in the core. h APP dys-
trophic neurites could be seen 
surrounding the core of classic 
cored plaques. i The classic 
cored plaque was immunoreac-
tive for  PrPC. APOE genotype 
of the respective case is shown 
in right lower corner of images 
of plaques stained for ApoE. 
Scale bar represents 50 µm 
and is applicable to all images. 
ApoE apolipoprotein E, APP 




plaques. Also, the center of the coarse-grained plaque was 
devoid of pTau staining in the presence of dystrophic neur-
ites. Of note, all cases with a high load of the coarse-grained 
plaque in the middle frontal gyrus section showed extensive 
pTau immunoreactivity. In addition, the coarse-grained plaque 
was, similarly to the classic cored plaque, immunoreactive for 
ApoE, APP, and  PrPC (Fig. 4). Immunohistochemical staining 
confirmed that the coarse-grained plaque was not immuno-
reactive for  PrPSc (See Supplementary Material 1, Fig. S7, 
Online Resource).
The coarse-grained plaque has unique characteristics 
compared to the cotton wool and classic cored plaque 
(Fig. 3a–l). At first sight, the coarse-grained plaque looks 
similar to the cotton wool plaque due to its size and mor-
phology observed with Aβ (aa 8-17; 6F/3D) immunostain-
ing. However, the coarse-grained plaque had a less-defined 
border compared to the distinct circumscribed cotton 
wool plaque. The cotton wool plaque is visible in both Aβ 
(Fig. 3e) and in H&E as cotton wool-like patches (Fig. 3f). 
Furthermore, the cotton wool plaque is only faintly visible in 
Congo-red (Fig. 3g) and seldom contains dystrophic neurites 
(Fig. 3h). The coarse-grained plaque also differed from the 
classic cored plaque (Fig. 3i–l). The most obvious difference 
is in Ø and morphology, while the Ø of classic cored plaques 
is commonly 30–50 µm with a central core surrounded by a 
corona of diffuse Aβ, the Ø of the coarse-grained plaques is 
mostly 50–100 µm and lacks this central core. Both plaque 
types contained fibrillar amyloid and could contain dys-
trophic neurites. In the classic cored plaque the swollen 
dystrophic neurites surround the amyloid that is condensed 
into a central core. In addition, classic cored plaques are 
more often observed in the deeper cortical layers (V–VI) 
than in the more superficial layers [14, 45].
Fig. 5  Aβ isoform composition of the coarse-grained plaque com-
pared to the cotton wool and classic cored plaque. a, b The coarse-
grained plaque was predominantly Aβ40 immunoreactive compared 
to Aβ42. c, d Strong immunostaining was also seen for AβN3pE and 
pSer8Aβ. This Aβ composition differed from that of the cotton wool 
plaque (e–h) and the classic cored plaque (i–l). e, f The cotton wool 
plaque showed a central staining for Aβ40, that was surrounded by an 
Aβ42 immunoreactive ring. g, h The cotton wool plaque was immuno-
reactive for AβN3pE and displayed a distinct halo immunoreactive for 
pSer8Aβ. i, j Classic cored plaques were predominantly Aβ42 com-
pared to Aβ40 immunoreactive. k, l Both AβN3pE and pSer8Aβ were 
detected in the entire classic cored plaque. Scale bar represents 50 µm 
and is applicable to all images. Aβ40 amyloid-beta 40, Aβ42 amyloid-
beta 42, AβN3pE truncated pyroglutamate Aβ, pSer8Aβ phosphorylated 
Aβ at serine 8
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The coarse‑grained plaque has a distinct Aβ 
isoform composition, being predominantly Aβ40 
immunoreactive
The coarse-grained plaque showed strong immunoreactiv-
ity for Aβ40, AβN3pE, and pSer8Aβ throughout the entire 
plaque (Fig. 5a, c, d). Interestingly, the coarse-grained 
plaque showed only little Aβ42 positivity (Fig. 5b). This 
weak Aβ42 immunoreactivity was observed more in the 
center than in the periphery of the plaque. Quantitative 
ELISA on laser-dissected coarse-grained plaques in two 
cases with a high load confirmed the relatively higher lev-
els of Aβ40 compared to Aβ42. The coarse-grained plaques 
in case #18 contained 324.94 pg/µl of Aβ40 and 13.59 pg/µl 
of Aβ42, making the Aβ40/Aβ42 ratio = 23.91. The coarse-
grained plaques in case #32 contained 264.24 pg/µl of Aβ40 
and 9 pg/µl of Aβ42, making the Aβ40/Aβ42 ratio = 29.36.
The Aβ isoforms composition and distribution in the 
coarse-grained plaque were different from that of other 
plaques (Fig. 5e–h for cotton wool plaque and Fig. 5i–l 
for classic cored plaque). Similar to the coarse-grained 
plaque, the cotton wool plaque was predominantly Aβ40, 
AβN3pE, and pSer8Aβ positive. However, in the cotton 
wool plaque, the Aβ42 was observed as a small outer ring 
surrounding the Aβ40-positive center. In the cotton wool 
plaque, pSer8Aβ immunoreactivity showed a dense center 
surrounded by a less prominent halo. AβN3pE distribu-
tion in cotton wool plaques was similarly as in coarse-
grained plaques seen throughout the plaque. The differ-
ence between the coarse-grained and classic cored plaque 
was most prominent in their Aβ40 and Aβ42 composition. 
The classic cored plaque consisted predominantly of Aβ42, 
which was seen both in the core and corona of the plaque. 
Aβ40 was mostly seen in the core and occasionally little 
in the corona.
Although the location of coarse-grained plaques is dif-
ferent from that of CAA, we directly compared the Aβ40 
and Aβ42 composition of the coarse-grained plaque to that 
of CAA due to a similar Aβ40 -predominance (Fig. 6). The 
classic cored plaque was used as a reference for plaque 
Aβ-isoform composition. In coarse-grained plaques, 
Aβ40 staining was somewhat tubular or trabecular-like. 
The Aβ40 immunoreactive trabeculae occasionally sur-
rounded the more rare Aβ42 (Fig.  6c arrowhead). The 
Fig. 6  Immunofluorescence for 
Aβ40 and Aβ42 in the coarse-
grained plaque compared to 
CAA-Type 1 and the classic 
cored plaque. a–c Double 
immunofluorescence labeling 
for Aβ40 (green) and Aβ42 
(red) confirmed the Aβ40 
predominance in coarse-grained 
plaques. c White arrowhead 
indicates an Aβ40 tubular-like 
structure filled with Aβ42. d–f 
CAA-Type 1 showed a similar 
Aβ40 to Aβ42 ratio as the coarse-
grained plaque. g–i Classic 
cored plaques were predomi-
nantly Aβ42 immunoreactive. 
Scale bar represents 50 µm and 
is applicable to all images. Aβ40 
amyloid-beta 40, Aβ42 amyloid-




coarse-grained plaque Aβ40 to Aβ42 ratio resembled that 
what is seen in CAA-Type 1, which showed a predomi-
nant presence of Aβ40 (Fig. 6d–f). As shown earlier, this 
was quite the opposite from what is seen in classic cored 
plaques (Fig. 6g–i).
The coarse‑grained plaque is associated 
with intense neuroinflammation and vascular 
pathology
To study Aβ-related disease mechanisms, immunostainings 
were performed for neuroinflammatory markers against 
complement (complement factor C4b), activated microglia 
(MHC-II/CD68), and reactive astrocytes (GFAP). These 
well-established markers have been shown to increase with 
AD pathology and are strongly associated with Aβ deposi-
tion [7, 24, 25]. The coarse-grained plaque showed intense 
immunoreactivity for C4b and activated microglia (Fig. 7a, 
b). C4b was seen throughout the plaque in a similar pat-
tern as Aβ as observed in our previous study [7]. MHC-II 
staining showed intense microglial activation covering the 
complete coarse-grained plaque. GFAP staining indicated 
the presence of reactive astrocytes around the coarse-grained 
plaque with mostly disrupted GFAP-positive processes 
within the plaque (Fig. 7c).
The neuroinflammatory response appeared to be dif-
ferent in the coarse-grained plaque compared to the cot-
ton wool (Fig. 7d–f) or classic cored plaque (Fig. 7g–i). In 
the cotton wool plaque, C4b (Fig. 7d) showed a ring-like 
immunostaining resembling the previous mentioned Aβ42 
staining (Fig. 5f). Microglial activation was negligible and 
astrocytic processes seemed to encapsulate the cotton wool 
plaque (Fig. 7e, f, respectively). In the classic cored plaque, 
C4b was found predominantly in the core and to a lesser 
extent in the corona and activated microglia were located 
between the Aβ core and corona. Astrocytic processes in 
the classic cored plaque seemed less disrupted than in the 
coarse-grained plaque. In Supplementary Material 1, Fig. 
S8, Online Resource, comparable results for all 3 plaque 
types are shown but then visualized by triple immunofluo-
rescence staining for C4b, CD68, and GFAP.
To study if the coarse-grained plaque was related to vas-
cular pathology, we immunohistochemically stained sequen-
tial sections for Aβ40, the capillary-pathology-associated 
Fig. 7  Neuroinflammatory 
response in the coarse-grained 
plaque compared to the cotton 
wool and classic cored plaque. 
a, b In the coarse-grained 
plaque, C4b was seen through-
out the plaque with intense 
MHC-II immunoreactivity. 
c GFAP-positive astrocytes 
showed disrupted processes. 
d–i C4b, MHC-II and GFAP 
showed a different staining 
pattern in the cotton wool (d–f) 
and classic cored plaque (g–i). 
Scale bar represents 50 µm and 
is applicable to all images
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marker norrin [23], and vascular basement membrane mark-
ers (laminin and collagen IV [53]) (see Fig. 8). The coarse-
grained plaque was both Aβ40 and norrin positive through-
out the entire plaque. Anti-laminin staining showed small 
punctate dots in areas, where coarse-grained plaques were 
found in the adjacent section. Collagen IV was not observed 
in coarse-grained plaques. The same markers were assessed 
in the cotton wool plaque (Fig. 8e–h) and the classic cored 
plaque (Fig. 8i–l). The most striking difference was observed 
after immunostaining for norrin. Although cotton wool 
plaques also showed norrin immunoreactivity, the staining 
had a more homogenous appearance than in coarse-grained 
plaques. Classic cored plaques were not immunoreactive for 
norrin. All 3 plaque types showed a punctate staining for 
laminin (Fig. 8c, g, k). Whereas in coarse-grained plaques 
the laminin dots were seen throughout the plaque, in cot-
ton wool plaques the dots were visible at the outer edges 
and in classic cored plaques the dots surrounded the core. 
Only in classic cored plaques, collagen IV positivity was 
sometimes vaguely seen as punctate dots surrounding the 
core (Fig. 8d, h, l). In Supplementary Material 1, Fig. S9, 
Online Resource, comparable results for all 3 plaque types 
are shown but then visualized by triple immunofluorescence 
staining for Aβ aa 1-16, norrin, and laminin.
3D visualization of the coarse‑grained plaque
To gain a deeper understanding of the coarse-grained plaque, 
we scanned the plaque in 3D using high-resolution CLSM 
in the right middle frontal gyrus of 5 different cases with 
coarse-grained plaques (Supplementary Material 1, Table S1 
for case details; Supplementary Material 1, Table S3 for # 
plaques per individual case, Online Resource). The combi-
nation of markers that was scanned was (1) Aβ40 & Aβ42; (2) 
Aβ, CD68, GFAP; (3) Aβ, norrin, laminin. Important to note 
for 3D interpretation is that due to fixation and pretreatment 
the tissue deforms and shrinks, especially in z-direction [15]. 
As a result, the originally 60 µm cut FFFF sections meas-
ured after mounting approximately 40 µm for combination 
1 (Aβ40 & Aβ42) and 30 µm for combination 2 (Aβ, CD68, 
Fig. 8  Vascular association of the coarse-grained plaque compared to 
the cotton wool and classic cored plaque. a–d Coarse-grained plaque 
showed immunoreactivity for Aβ40, norrin, and laminin but not for 
collagen IV. e–h Although the cotton wool plaque was positive for the 
same markers, staining morphology differed compared to the coarse-
grained plaque. i–l Classic cored plaque has an Aβ40 positive core, 
was not immunoreactive for norrin, and showed a punctate staining 
for both laminin and collagen IV. Scale bar represents 50 µm and is 
applicable to all images. Aβ40 amyloid-beta 40
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GFAP) and 3 (Aβ, norrin, laminin). Due to this ‘flattening’ 
in z-direction, the plaque, which is assumed to be a sphere, 
appeared as an ovoid.
3D analysis of large coarse‑grained plaques reveals an Aβ40 
shell structure
A total of 38 coarse-grained plaques stained for Aβ40 & Aβ42 
were scanned (see Supplementary Material 1, Table S3, 
Online Resource). 3D CLSM imaging showed that the 
predominant Aβ40 staining showed a trabecular-like and 
sometimes even tubular-like morphology in the coarse-
grained plaque, confirming our 2D observations (Fig. 9 and 
Supplementary Materials 2 and 3, Online Resource). This 
trabecular appearance was most prominent at the surface 
of the plaque. Interestingly, in 61% of all scanned coarse-
grained plaques, the Aβ40 formed an outer shell around the 
lesser Aβ42 (Supplementary Material 1, Table S3, Online 
Resource). This was especially prominent in the larger 
coarse-grained plaques (Ø ≈ 80 μm; larger plaque in Fig. 9 
Table 2  Staining summary per plaque-type
(Immuno)histochemical staining summary per plaque-type is given and indicated as follows: −, no staining; +−, some positive staining; +, posi-
tive staining; ++, prominent positive staining. Supplementary Material 1, Table S1, Online Resource, for antibody and staining details
Staining The coarse-grained plaque The cotton wool plaque The classic cored plaque
Aβ (aa 8-17; 6F/3D)
H&E Tissue distortion Circumscript defined patches Visible core
Congo red ++; fibrillar amyloid throughout the 
plaque
−; not fibrillar ++; fibrillar amyloid condensed into 
a core
pTau ++; neuropil threads
+−; dystrophic neurites
++; neuropil threads +−; dystrophic neurites
APP +; dystrophic neurites +− +; dystrophic neurites
ApoE ++; throughout the plaque ++; throughout the plaque ++; in the core; +−; in the corona
PrPC +; throughout the plaque +; throughout the plaque ++; in the core; +−; in the corona
Aβ40 ++; throughout the plaque as fibrillary 
or tubular structures, 61% as shell 
surrounding the lesser Aβ42
++; homogenous throughout the 
plaque
++; in the core; +−; in the corona
Aβ40 +−; in the plaque center, sometimes 
co-localizing with Aβ40
+; outer ring ++; in both the core and the corona
AβN3pE ++ ++ ++
pSer8Aβ ++ ++; intense stained plaque with diffuse 
halo
++
C4b ++; throughout the plaque +; outer ring +; in the core; +−; in the corona
CD68 ++; within Aβ-devoid pores +−; occasionally 1 cell body within 
the plaque
+; in-between the core and the corona
MHC-II ++; within Aβ-devoid pores +−; occasionally 1 cell body within 
the plaque
+; in-between the core and the corona
GFAP +; cell bodies are often found within 
the plaque
+; disrupted processes mostly staining 
the outer plaque edges
+
Norrin ++; fibril-like throughout the plaque ++; homogenous throughout the 
plaque
−
Laminin +; small punctate dots throughout the 
plaque
+; small punctate dots throughout the 
plaque
+; small punctate dots surrounding 
the core




and Supplementary Material 2, Online Resource, and the 
plaque in Supplementary Material 3, Online Resource). 
In the smaller coarse-grained plaques (Ø ≈ 50 μm), the Aβ 
isoform segregation was less present and Aβ40 and Aβ42 
more often co-localized (smaller plaque in Fig. 9, and Sup-
plementary Material 2, Online Resource).
Fig. 9  3D composition of Aβ40 and Aβ42 in the coarse-grained 
plaque. CLSM 3D image of two coarse-grained plaques stained for 
Aβ40 (a; green) and Aβ42 (b; red) with Aβ40/Aβ42 overlay in c, is 
shown. In the smaller coarse-grained plaque (upper plaque) Aβ40 
and Aβ42 is co-localized. In the larger coarse-grained plaques (lower 
plaque) Aβ40 showed an outer shell structure, surrounding the lesser 
present Aβ42. White cross in XY indicates the same point in space 
as the white cross in XZ and YZ. Scale bar represents 10 µm and is 
applicable to all images. Aβ40 amyloid-beta 40, Aβ42 amyloid-beta 42, 
CLSM confocal laser scanning microscopy
Fig. 10  3D composition of neuroinflammation and vascular attribu-
tion in the coarse-grained plaque. Representative CLSM 3D images 
are shown for neuroinflammation (top row) and vascular attribution 
(bottom row) in and near the coarse-grained plaque. CD68 or GFAP 
immunoreactivity was found throughout the coarse-grained plaque 
(top row). Most coarse-grained plaques were in direct contact with a 
vessel, which appeared as a string vessel for this particular plaque. 
White cross in XY indicates the same point in space as the white 
cross in XZ and YZ. Scale bar represents 10 µm and is applicable to 




Neuroinflammatory response is seen 
throughout the coarse‑grained plaque
A total of 36 coarse-grained plaques stained for neuroin-
flammatory markers (Aβ, CD68, and GFAP) were scanned 
(Supplementary Material 1, Table S3, Online Resource). 
Although not all Aβ-devoid pores were filled with CD68 or 
GFAP, both markers were found throughout the plaque in a 
rather unorganized manner, confirming our 2D-based obser-
vations (Fig. 10 upper row a–d; Supplementary Materials 4 
and 5, Online Resource).
3D analysis hints to a vascular component 
in the coarse‑grained plaque
Forty-four coarse-grained plaques stained for vascular mark-
ers (Aβ, norrin, and laminin) were scanned (Supplementary 
Material 1, Table S3, Online Resource). Based on 2D obser-
vations of the plaque’s Aβ40 and norrin immunoreactivity, 
the tubular structures, and the plaque’s association with 
CAA-affected vessels, we expected CAA vessels to pen-
etrate the coarse-grained plaque in 3D. This was, however, 
not observed with CLSM analysis. We did observe that at 
least 37/44 (84%) of scanned coarse-grained plaques were in 
direct contact with a vessel (Fig. 10 bottom row e-h; Supple-
mentary Materials 6 and 7, Online Resource). Seven of the 
44 scanned plaques were not in direct contact with a vessel. 
Five of those 7 could not be completely scanned in z-direc-
tion, and therefore, their potential vessel connection could 
be missed, making the 84% most likely an underestimation. 
A little bulge in laminin, possibly reflecting the localization 
of a pericyte (mean width ≈ 7 μm) [4], was often observed, 
where the plaque touched the vessel. Although the touching 
vessel was not immunoreactive for norrin, norrin positive 
threads within the plaque were closely connected to the ves-
sel (Supplementary Materials 6 and 7, Online Resource). In 
addition, similar to what was observed in 2D DAB staining, 
laminin staining was seen as punctate dots although with 
lesser intensity.
Discussion
In this study we defined a divergent plaque-type, called the 
coarse-grained plaque, with distinct characteristics com-
pared to earlier described plaques. Using anti-Aβ immu-
nostaining, the coarse-grained plaque was defined by its 
size (30–100 µm), multi-cored coarse-grainy appearance, 
Aβ-devoid pores, and an ill-defined border. Increased pres-
ence of the coarse-grained plaque was related to an early 
disease onset in AD, a homozygous APOE ε4 status, and 
the presence of CAA-Type 1. The coarse-grained plaque 
was not observed in Aβ-positive clinically non-demented 
cases. Together, these results highlight the association of this 
plaque-type with the clinical manifestation of AD. In-depth 
characterization revealed that the plaque contains fibrillar 
amyloid, was mostly composed of Aβ40, and showed strong 
immunoreactivity for neuroinflammation- as well as vascu-
lar pathology-associated markers. In-depth 3D assessment 
Fig. 11  Hypothetical illustration of the coarse-grained plaque’s ori-
gin. This figure illustrates the coarse-grained plaques’ similarities 
and differences with the two other forms of Aβ deposits, being paren-
chymal plaques illustrated by the classic cored plaque and vascular-
located Aβ illustrated by CAA. We placed the coarse-grained plaque 
in-between parenchymal and vascular aggregates, based on its paren-
chymal perivascular localization, microglial activation, Aβ40 predom-
inance and norrin immunoreactivity. See “Discussion” section for 
explanation. Aβ amyloid-beta, Aβ40 amyloid-beta 40, Aβ42 amyloid-
beta 42, CAA cerebral amyloid angiopathy
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exposed an Aβ40 shell structure in the larger coarse-grained 
plaques and a direct vascular connection.
Based on the plaque’s characteristics observed in this 
study, we hypothesize that the coarse-grained plaque evolves 
at the parenchymal border of the capillary blood–brain bar-
rier as illustrated in Fig. 11. To discuss the placement of 
the coarse-grained plaque, we made a direct comparison 
with the classic cored plaque and CAA-Type 1 as a refer-
ence for parenchymal and vascular deposited Aβ, respec-
tively. In the classic cored plaques predominant Aβ42 pre-
cipitates, after neuronal excretion, in the brain parenchyma, 
most likely due to the increased aggregation properties and 
decreased drainage of Aβ42 compared to Aβ40 [28]. The 
aggregated Aβ becomes increasingly fibrillar and is then 
associated with complement factors, reactive astrocytes, 
and activated microglia [7, 17, 26, 54]. Dystrophic neur-
ites immunoreactive for APP or pTau can be observed near 
the amyloid containing aggregates [16]. In case of CAA, 
the excessive Aβ is also produced neuronally [22]. How-
ever, the excreted Aβ than consists mainly of Aβ40, which 
is hypothesized to travel further than the plaque-associated 
Aβ42 due to increased solubility and only aggregates once it 
reaches the (peri)vasculair drainage system [22]. The com-
plement cascade becomes also activated and dystrophic 
neurites can be found surrounding the congophilic vessels 
[37, 38, 56]. However, different from plaques, microglial 
and macrophage activity markers in CAA do not seem to 
be increased compared to control vessels [56]. Only when 
Aβ is found to be dyshoric, meaning the Aβ is deposited in 
the parenchyma around the amyloid-laden vessel, microglia 
activation is present in CAA [41]. When CAA is located in 
the capillaries, referred to as CAA-Type 1, the vessels are 
immunoreactive for the norrin protein [23]. We placed the 
coarse-grained plaque between the classic cored plaque and 
CAA-Type 1, since it showed similarities and differences 
with both types of Aβ deposits. Similar to the classic cored 
plaque, the coarse-grained plaque is localized within the 
brain parenchyma and is immunoreactive for complement 
and associated with activated microglia and astrocytes [7]. 
The amyloid structure of the coarse-grained plaque most 
likely favours a strong binding and activation of complement 
factors, which in turn could act as opsonins for phagocy-
tosis carried out by microglia [33, 46, 57]. APP and  PrPC 
immunoreactivity in the coarse-grained plaque could reflect 
dystrophic neurites, indicating damage to the surrounding 
axons. Similar to CAA-Type 1, the coarse-grained plaque 
mainly consists of Aβ40 and is immunoreactive for norrin [6, 
23]. Different to CAA, the vascular morphology in coarse-
grained plaques is not so obvious. However, using anti-Aβ 
immunostaining we did observe tubular-like structures in the 
coarse-grained plaque. Together with the dot-like laminin 
immunoreactivity, we speculate these tubular structures 
to be vascular remnants with the laminin representing the 
collapsed vascular basement membrane. Furthermore, the 
coarse-grained plaque was predominantly observed in sulcal 
fundi, in which the vascular density is higher than in gyral 
crowns [2]. Although CAA-affected vessels were often noted 
in the proximity of coarse-grained plaques and most coarse-
grained plaques were in direct contact with a vessel, these 
vessels were not affected by CAA nor did they penetrate the 
plaque. For these reasons, we assume that the Aβ aggrega-
tion in coarse-grained plaque does not start within the vessel 
wall as in CAA, but rather starts at the parenchymal border 
of the capillary blood–brain barrier, which is similar to the 
location of dyshoric Aβ in CAA-Type 1. Why the Aβ40 in 
case of CAA is capable of crossing the blood–brain bar-
rier and in case of the coarse-grained plaque is not, remains 
elusive. The observed Aβ40 shell structure surrounding the 
lesser Aβ42 in larger coarse-grained plaques is remarkable. 
Although we are unsure of the essence of the shell structure, 
we hypothesize it to be related to the aggregation properties 
and the development of the coarse-grained plaque.
Similar amyloid plaque structures as what we define 
here as the coarse-grained plaque have sporadically been 
described by others. The coarse-grained plaque is com-
parable to the previously described ‘fibrous’ or ‘fibrillar’ 
plaque described by Schmidt et al. and Dickson & Vickers, 
respectively [14, 45]. Although studied in a small cohort, 
both groups show that this type of plaque is associated 
with clinical symptoms of dementia, which is in line with 
our results. This association was not found for the classic 
cored plaque, since this plaque was also observed in cases 
without clinical symptoms [14]. Furthermore, Schmidt 
et al. concluded that these fibrous—or what we deemed 
‘coarse-grained’—plaques are rare in AD, but are particu-
lar common in Down syndrome cases with AD pathology 
[45]. With a mean age of death at 78 years, it is most 
likely that the AD cohort studied by Schmidt et al. mainly 
consisted of LOAD cases. After the reported observation 
25 years ago, the coarse-grained plaque escaped attention 
and was not included in the currently most used plaque 
categorization scheme [48, 51]. To our knowledge, we 
are the first to perform such in-depth characterization for 
the coarse-grained plaque and to report that this plaque is 
especially prominent in EOAD.
As Aβ pathology starts long before clinical symptoms 
arise and comes in a myriad of different morphologies [27, 
48], it is important to study Aβ deposits that are clinically 
relevant. The fact that coarse-grained plaques were only 
observed in cases with clinical symptoms of AD and not 
in non-demented Aβ-positive cases, indicates the clini-
cal relevance of this plaque type. In addition, the coarse-
grained plaque contains Aβ isoforms that correlate with 
clinical disease progression. Previously, Rijal Upadhaya 
et al. showed that both Aβ42 and Aβ40 were detected in 
brain homogenates of Aβ-positive but cognitively-healthy 
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cases [43]. In cases with pre-clinical AD, AβN3pE was also 
detectable, while pSer8Aβ was only detected in cases 
with clinical dementia due to AD. The immunoreactiv-
ity of the coarse-grained plaque for pSer8Aβ is in line 
with the observation that this plaque is only seen in clini-
cally demented cases. This could be a relevant finding for 
exploring biomarkers reflecting specific Aβ deposits that 
could distinguish between clinical subgroups in AD .
As EOAD cases are likely to be genetically predis-
posed, the occurrence of the coarse-grained plaque could 
be related to genetic factors. However, extensive genetic 
screening for the known mendelian mutations in APP, 
PSEN1, and PSEN2 for AD could not link the coarse-
grained plaque to the functional impairment in one of 
those genes such as found for the cotton wool plaque, 
which is linked to an exon 9 deletion in the PSEN1 gene 
[10]. We did observe an association with the most preva-
lent genetic risk factor for AD, being APOE ε4. Interest-
ingly, mice transgenic for human APOE ε4 and a familial 
APP mutation (E4FAD mice) showed both larger plaques 
and increased neuroinflammation compared to APOE ε4 
negative FAD mice [2]. Although at first sight the plaques 
stained with thioflavin S in E4FAD mice may resemble 
the coarse-grained plaque, the mouse plaques were pre-
dominantly Aβ42 positive, which is an important differ-
ence with the coarse-grained plaque. In our view it is too 
soon to draw any conclusions on the functional correlation 
with APOE ε4, especially since at least one-third of the 
cases with a frequent degree of coarse-grained plaques 
lacked any ε4 allele. This makes it most likely that besides 
APOE also other (genetic) factors come into play. Since 
the coarse-grained plaque was more prevalent in EOAD 
than in LOAD, the plaque is likely to be genetically predis-
posed. Therefore, it would be interesting for future studies 
to investigate whether we can identify additional genetic 
mutations or variants in individuals with coarse-grained 
plaques.
Some limitations may apply to this work. We are well 
aware that post-mortem studies are cross-sectional, mak-
ing our hypothesis on plaque-development speculative. It 
would be interesting to study the plaque’s development in 
a mechanistic model. However, this would require more in-
depth background on the pathology (e.g., proteome) of the 
plaque, the genotype, and the clinical phenotype of cases 
with coarse-grained plaques. In this study, CD68 was used 
as a microglial activation marker in 3D visualization. It 
would be interesting to extend this microglia marker panel 
with other activation markers as well as more microglia 
specific markers (e.g., P2Y12, TMEM119, Iba1) to gain 
better insights on the microglial involvement.
We observed the coarse-grained plaque to be espe-
cially prominent in the neocortex, which is one of the first 
regions to develop Aβ pathology [51]. The coarse-grained 
plaque, similar to other plaques, is likely to be region spe-
cific [7, 51]. In this study we observed that the coarse-
grained plaque was predominantly found in the frontal and 
parietal regions and to a lesser extend also in the temporal 
and occipital regions of the neocortex. Future work could 
focus on the presence of coarse-grained plaques in differ-
ent pathology stages, as well as in different clinical AD 
phenotypes.
Conclusion
In this study, we describe and define a new type of Aβ 
deposit, referred to as the ‘coarse-grained plaque’. Its char-
acteristics are different from other Aβ deposits. We provide 
a morphological and biochemical definition for the coarse-
grained plaque, supporting that this deposit is unique, with 
specific clinical and etiological associations. Associated 
disease mechanisms such as neuroinflammation and vas-
cular attribution, as well as the structure and biochemical 
composition of Aβ may lie at the cause of morphological 
differences between Aβ deposits. Disentangling specific Aβ 
deposits between AD subgroups may be important in the 
search for disease-mechanistic-based therapies in the near 
future.
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